What Next for Sintx Technologies, Inc. (SINT) Stock After Today’s Big Decline?

The stock of Sintx Technologies, Inc. (NASDAQ:SINT) is a huge mover today! The stock increased 2.36% or $0.05 during the last trading session, reaching $2.17. About 970,523 shares traded. Sintx Technologies, Inc. (NASDAQ:SINT) has declined 84.04% since September 13, 2018 and is downtrending. It has underperformed by 84.04% the S&P500.
The move comes after 6 months negative chart setup for the $4.25 million company. It was reported on Sep, 13 by Barchart.com. We have $2.02 PT which if reached, will make NASDAQ:SINT worth $297,430 less.

More notable recent Sintx Technologies, Inc. (NASDAQ:SINT) news were published by: Benzinga.com which released: “22 Healthcare Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” on September 10, 2019, also Benzinga.com with their article: “35 Stocks Moving In Monday’s Pre-Market Session – Benzinga” published on July 29, 2019, Globenewswire.com published: “SINTX TECHNOLOGIES HIRES STRATEGIC VP Nasdaq:SINT – GlobeNewswire” on April 15, 2019. More interesting news about Sintx Technologies, Inc. (NASDAQ:SINT) were released by: Finance.Yahoo.com and their article: “Why This Analyst Set A $3 Price Target On SINTX Shares – Yahoo Finance” published on September 12, 2019 as well as Seekingalpha.com‘s news article titled: “New coverage – healthcare – Seeking Alpha” with publication date: September 12, 2019.

Sintx Technologies, Inc., a biomaterial company, develops, makes, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company has market cap of $4.25 million. The firm offers silicon nitride implants to surgeons and hospitals for use in cervical and thoracolumbar spine surgery under the Valeo brand. It currently has negative earnings. It also provides a line of non-silicon nitride spinal fixation products to address spinal deformity and degenerative conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.